Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
KLRS
Kalaris Therapeutics, Inc.
CAPPED RATING
Kalaris Therapeutics, Inc. (KLRS) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.2
/ 5.0
C
Value
B+
Factor Score
3.7
/ 5.0
Growth
C-
Factor Score
2.1
/ 5.0
Profitability
D+
Factor Score
1.7
/ 5.0
Momentum
D-
Factor Score
0.9
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-1.0
EV / EBITDA
0.9
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-59.3%
Price Return 12M
-67.3%
Catalyst Signal
0.00
Market Cap
$39.5M
TTM Revenue
N/A
Price / Sales
N/A
ROE
-97.2%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B+ (3.7) | C- (2.1) | D+ (1.7) | D- (0.9) | C+ (2.6) | C (2.2) |
| 2026-11-06 | C+ (2.5) | C- (2.1) | D+ (1.8) | D (1.2) | C+ (2.7) | C- (2.1) |
| 2026-10-30 | C+ (2.5) | C- (2.1) | D+ (1.8) | D (1.3) | C+ (2.7) | C- (2.1) |
| 2026-10-23 | C+ (2.5) | C- (2.1) | D+ (1.8) | D (1.2) | C+ (2.6) | C- (2.0) |
| 2026-10-16 | C+ (2.5) | C- (2.1) | D+ (1.8) | D- (1.1) | C+ (2.6) | C- (2.0) |
Page
1
of
4